Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 798 results for "mg johnson"

Deception for Drugs: 'Doctor Shopping' Among Young Adults

Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 19752012. Volume 1: secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan; 2013. Results ... Diabetes Care, 3 weeks ago

Mitchell Johnson to miss start of CLT20, doubtful for rest of tourney

, 12:41 [IST] Melbourne, Sep 17: Kings XI Punjab 's Australian paceman Mitchell Johnson will miss the start of the Champions League Twenty20 ( CLT20 ) and is also in doubt for the rest of the tournament due to a rib injury, Cricket Australia ...
 ThatsCricket1 month ago

Osteopontin in Patients With T1DM and Complications

Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontinda molecule for all seasons. QJM 2002;95:313 Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis ...
 General Medicine eJournal1 month ago

Pharmalink Elects Bengt Julander as Chairman

(Date:10/14/2014)... Johnson & Johnson (NYSE: JNJ ... the third quarter of 2014, an increase of ... 2013. Operational results increased 5.8% and the negative ... 11.6%. International sales decreased 0.3%, reflecting operational growth ... 1.3%.
 Bio-Medicine6 days ago Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien  Franklin Credit Management Corporation3 weeks ago Regulatory Filing, Business Reorganization, Voluntary Product Recall, Certification, and Research Grant - Research Reports on Mohawk, Johnson Controls, Baxter, Boston Scientific and Thermo Fisher  Securities Technology Monitor4 weeks ago Technical Updates, Upcoming Events, Awards Ceremony, and NDA Filing - Research Reports on Mead Johnson, Philip Morris, Johnson Controls, Actavis and Bristol-Myers  Scottrade1 month ago
Surgical Products

Sedasys announces launch of new sedation system in the U.S.

Five bladder cancer experts to receive $250,000 research grants from Johns Hopkins Imperial researchers plan to test DTP3 drug in multiple myeloma patients Group Health's HMO Medicare Advantage plan earns 5-Star rating from CMS Johnson & ...
 News-Medical.Net6 days ago Sedasys Launches Computer-Assisted Personalized Sedation System  Surgical Products4 days ago US Launch Of SEDASYS® System Commences  PR Newswire6 days ago
Securities Technology Monitor

JOHNSON & JOHNSON : Alios : BioPharma Presented Positive Results of Its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Challenge Study in Adults Infected With Respiratory Syncytial Virus (RSV) at IDWeek

- Alios BioPharma, Inc. presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA.The study was ...
 4 Traders1 week ago Alios BioPharma Presented Positive Results of Its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Challenge Study in Adults Infected With Respiratory Syncytial Virus (RSV) at IDWeek  Town Hall1 week ago

MEAD JOHNSON NUTRITION : "Reducing Proinflammatory Response" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Diabetes Week -- A patent application by the inventors Hondmann, Dirk ( Winnetka, IL ); van Tol, Eric A.F. ( Arnhem, NL ); Gross, Gabriele ( Nijmegen, NL ); Schoemaker, Marieke H. ( Rhenen, NL ); Lambers, ...
 4 Traders2 weeks ago Mead Johnson Nutrition : Patent Application Titled "Reducing the Risk of Autoimmune Disease" Published Online  4 Traders2 weeks ago Patent Application Titled "Phenylephrine Resinate Particles Having Good Auc" Published Online  Pharmacy Choice1 week ago

Executive departures a big blow for Eskom

The resignations of Steve Lennon and Erica Johnson have dealt a blow to the troubled state utility's already overburdened executive committee. By Lisa Steyn. The resignations of Steve Lennon and Erica Johnson from Eskom have dealt a blow to the ... weeks ago Blow as Eskom loses two top executives  Mail & Guardian Online3 weeks ago

JOHNSON & JOHNSON : New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal BARCELONA, Spain, September 2, 2014 - Janssen Research & Development, LLC (Janssen) and its development partner, Bayer ...
 4 Traders1 month ago Once-daily Xarelto® indicates benefit in the first trial to evaluate prospective use in atrial fibrillation (AF) patients undergoing cardioversion  Medical News Today1 month ago

Chemokine Mediated Monocyte Trafficking into the Retina: Role of Inflammation in Alteration of the Blood-Retinal Barrier in Diabetic Retinopathy

Abstract Inflammation in the diabetic retina is mediated by leukocyte adhesion to the retinal vasculature and alteration of the blood-retinal barrier (BRB). We investigated the role of chemokines in the alteration of the BRB in diabetes. Animals ...
 Plosone.org2 hours ago Progression of Early Retinal Dysfunction in Diabetes  General Medicine eJournal1 month ago Targeted Retinoblastoma Management  General Medicine eJournal1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less